Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PCSA 
Processa Pharmaceuticals Inc (PCSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PCSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.09% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.65M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 1.31 | 52 Weeks Range 0.15 - 1.50 | Updated Date 08/29/2025 |
52 Weeks Range 0.15 - 1.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.31 |
Earnings Date
Report Date 2025-08-11 | When After Market | Estimate -0.23 | Actual -0.25 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -102.62% | Return on Equity (TTM) -212.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2604953 | Price to Sales(TTM) - |
Enterprise Value 2604953 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 50349100 | Shares Floating 42593870 |
Shares Outstanding 50349100 | Shares Floating 42593870 | ||
Percent Insiders 12.08 | Percent Institutions 5.99 |
Upturn AI SWOT
Processa Pharmaceuticals Inc
Company Overview
History and Background
Processa Pharmaceuticals, Inc. was founded in 2017. It focuses on developing next generation chemotherapy treatments to improve the efficacy and safety for patients suffering from cancer.
Core Business Areas
- Clinical Development: Processa focuses on the clinical development of drugs targeting unmet medical needs in cancer treatment. This includes conducting clinical trials and seeking regulatory approvals.
Leadership and Structure
David Young is the CEO. The organizational structure is typical for a small pharmaceutical company, with departments for research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Next Generation Chemo Therapies: Processa is focused on clinical development of novel molecules and their therapeutic potential in treating various cancers with no specific market share data available. Competitors include major pharmaceutical companies with established chemotherapy drugs, such as Pfizer (PFE), Novartis (NVS) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with a focus on innovation and drug development. The oncology segment is a major area of growth, driven by increasing cancer prevalence and advancements in treatment options.
Positioning
Processa is a relatively small player focused on niche oncology drug development. Its competitive advantage lies in its novel approach to chemotherapy agents.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Processa is positioned to capture a small portion of this TAM through its pipeline of drug candidates, contingent on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel drug development approach
- Focused on unmet needs in oncology
- Experienced management team
Weaknesses
- Limited financial resources
- High risk associated with drug development
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PFE
- NVS
- BMY
Competitive Landscape
Processa faces significant competition from established pharmaceutical companies with greater resources and existing market presence. Its success hinges on the differentiation and efficacy of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by the advancement of its drug candidates through clinical trials.
Future Projections: Future growth is contingent on successful clinical trial outcomes, regulatory approvals, and potential commercialization or partnerships.
Recent Initiatives: Recent initiatives include advancing its clinical pipeline and securing additional funding for research and development.
Summary
Processa Pharmaceuticals is a clinical-stage pharmaceutical company with a focus on developing next-generation chemotherapy treatments, making it a high-risk, high-reward investment. Their current pipeline is advancing, and its competitive advantages lie in its novel approach to chemotherapy agents, however, its a smaller player with limited financial resources. Clinical trial successes will determine their future success, and thus the stock performance. The company needs to focus on securing funding to progress its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Processa Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Hanover, MD, United States | ||
IPO Launch date 2017-10-10 | CEO & Director Mr. George K. Ng Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | |
Full time employees 10 | |||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.